Article Text

PDF
Prolactin: a new therapeutic target in peripartum cardiomyopathy
  1. Hatice Yamac1,
  2. Insa Bultmann1,
  3. Karen Sliwa2,
  4. Denise Hilfiker-Kleiner1
  1. 1Department of Cardiology and Angiology, Medical School Hannover, Hannover, Germany
  2. 2Hatter Cardiovascular Research Institute, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
  1. Correspondence to Dr Denise Hilfiker-Kleiner, Department of Cardiology and Angiology, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, Germany; hilfiker.denise{at}mh-hannover.de

Abstract

Peripartum/postpartum cardiomyopathy (PPCM) is a potentially life-threatening disease of uncertain aetiology in previously healthy women. Clinical and experimental data suggested inflammation, autoimmune processes, apoptosis and endothelial dysfunction as typical pathophysiological features of PPCM. Recent data discovered that unbalanced peri/postpartum oxidative stress linked to proteolytic cleavage of the nursing hormone prolactin into a potent anti-angiogenic, pro-apoptotic and pro-inflammatory 16-kDa subform as a potential pathomechanism for the development of PPCM. Consistent with these idea, blockade of prolactin by bromocriptine, a dopamine D2 receptor agonist, prevented the onset of disease in an experimental model of PPCM and appeared successful in small pilot trials with respect to prevention or treatment of PPCM in patients. Here we highlight the current state of knowledge on diagnosis of PPCM, provide novel insights into the pathophysiology behind the disease and outline potential consequences for the clinical management and treatment options for patients at risk for or with PPCM.

Statistics from Altmetric.com

Footnotes

  • Funding Original work from our group in this review was supported by the Foundation Leducq and the German Research Foundation.

  • Competing interests None.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.